Monoclonal Antibodies: US$ 34 Billion Approach to Cancer
The past few years have witnessed the emergence of monoclonal antibodies as therapeutic modality for cancer. Monoclonal antibodies are designed to selectively target cancer cells and elicit various responses thereby obliquely protecting the non cancerous cells. This attribute of mAbs alongwith increasing potential of the oncology market has prompted pharmaceutical giants to concentrate a sizable portion of their R&D on cancer mAbs.
View full press release